Intuitive Surgical reported quarterly revenue of $2.87 billion, up 18.8% year-over-year, and delivered EPS of $2.53, outperforming consensus estimates by $0.26. While top-line growth was driven by robust adoption of its da Vinci platforms and consumables, management issued guidance below street forecasts for the coming quarter, reflecting ongoing capital spending discipline among health systems and a longer visibility window into procedure volumes.

According to the latest 13F filing, Alpha Cubed Investments LLC raised its position by 13.0%, adding 10,677 shares to reach a total holding of 92,600 shares, equivalent to 1.4% of its portfolio. Valley Wealth Managers, Tandem Investment Advisors, Strategic Advisors LLC, AE Wealth Management and LRI Investments all increased stakes by 4.5% to 63.3% during the quarter, underscoring sustained conviction among active managers. Institutional ownership now stands at 83.6%, highlighting continued confidence from large-scale investors.

The FDA expanded clearance for the da Vinci 5 system into select advanced cardiac procedures, opening a sizeable new addressable market for both capital systems and recurring instrument sales. On the sell-side, TD Cowen initiated coverage with a strong-buy, Barclays reaffirmed its buy rating and HSBC issued a bullish appraisal, collectively reinforcing positive analyst sentiment. Offsetting this, several firms trimmed near-term price targets, creating a mixed valuation backdrop for momentum-driven flows.

Company insiders have reduced their holdings in recent months: director Gary Guthart disclosed sales of 27,300 shares, SVP Mark Brosius sold 4,500 shares and EVP Henry Charlton exited 13,731 shares. Executive VP Myriam Curet also disposed of 230 shares. While these transactions represent a small fraction of total insider ownership, they have the potential to trigger near-term profit-taking among momentum investors.